Bristol Myers Squibb (BMS) has officially opened its first Innovation Centre in China, located in Beijing's Economic-Technological Development Area (BioPark). The centre will serve as a hub for fostering strategic partnerships across the entire biopharmaceutical value chain in China, focusing on oncology, haematology, immunology, cardiovascular disease (CVD), neuroscience and novel therapeutic modalities. It will operate alongside BMS's existing R&D centre in Shanghai, aiming to accelerate the introduction of global first-in-class and best-in-class therapies into China and facilitate the global development of innovations originating from China.

The launch coincided with BMS's third annual China Partnership Week, which featured an innovation forum and the signing of multiple strategic collaboration memoranda. These initiatives are central to the company's China 2030 Strategy, which seeks to deepen its integration into China's innovation ecosystem. BMS highlighted that China's participation in its highest-priority global clinical trials is now close to 100%, underscoring the country's growing strategic importance in its global R&D network.

PharmCube's NextBiopharm® database lists 78 BMS products registered in China out of 121 launched globally, while most of the company's projects in the country are in preclinical stage. Click here to request a free trial for NextBiopharm®.